This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2002-2003.
Company Filing History:
Years Active: 2002-2003
Title: Kiren A Vyas: Innovator in Pharmaceutical Delivery Systems
Introduction
Kiren A Vyas is a notable inventor based in Canterbury, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative delivery systems. With a total of 2 patents to his name, Vyas is recognized for his work in enhancing the efficacy of high solubility pharmaceuticals.
Latest Patents
Vyas's latest patents focus on a biphasic controlled release delivery system designed for high solubility pharmaceuticals, such as the antidiabetic metformin HCl salt. This innovative system provides a dosage form that ensures prolonged gastric residence, allowing for a dosing regimen of at least one gram of metformin once daily. The delivery system consists of an inner solid particulate phase made of uniform granules containing the pharmaceutical and various polymers, along with an outer solid continuous phase that embeds these granules. This design not only improves the control of plasma glucose but also offers methods for forming and utilizing the delivery system in diabetes treatment.
Career Highlights
Kiren A Vyas is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research and development efforts in pharmaceutical technologies. His work has been instrumental in creating effective solutions for patients requiring high solubility medications.
Collaborations
Throughout his career, Vyas has collaborated with esteemed colleagues, including Peter Timmins and Andrew B Dennis. These partnerships have fostered a collaborative environment that enhances innovation and drives progress in pharmaceutical research.
Conclusion
Kiren A Vyas stands out as a significant figure in the realm of pharmaceutical innovations. His contributions, particularly in the development of controlled release delivery systems, have the potential to greatly impact the treatment of diabetes and improve patient outcomes.